Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation
Peripheral blood stem cells are now considered the standard source of stem cells for
autologous stem cell transplants. Unfortunately, there is still a 20-30% chance that
inadequate numbers of stem cells will be collected, resulting in prolonged recovery of cell
counts after transplantation and increased transfusion dependence. There is also a
significant economic burden associated with remobilization and a risk that delays in
collecting sufficient numbers of stem cells can result in an increased chance of disease
recurrence prior to transplantation.
Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Rate of successful collection with early introduction of plerixafor in patients predicted to be poor mobilizers
The primary endpoint of the study will be the rate of successful collection with early introduction of plerixafor in patients predicted to be poor mobilizers based on peripheral blood CD34+ cell counts or CD34+ cell collection efficiency after 2 consecutive days of apheresis. Success will be defined as the ability to avoid a second mobilization attempt. Results will be compared to matched historical controls.
Day 2 of apheresis
Jack W Hsu, MD
University of Florida
United States: Institutional Review Board
|Shands Cancer Hospital at the University of Florida||Gainesville, Florida 32608|